Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Actinium Pharmaceuticals (ATNM) Revenue (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Revenue for 4 consecutive years, with $90000.0 as the latest value for Q3 2025.

  • Quarterly Revenue changed N/A to $90000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $90000.0 through Dec 2025, changed N/A year-over-year, with the annual reading at $90000.0 for FY2025, N/A changed from the prior year.
  • Revenue for Q3 2025 was $90000.0 at Actinium Pharmaceuticals, up from $45000.0 in the prior quarter.
  • The five-year high for Revenue was $940000.0 in Q1 2022, with the low at $23000.0 in Q4 2021.
  • Average Revenue over 3 years is $283000.0, with a median of $161500.0 recorded in 2021.
  • Peak annual rise in Revenue hit 51.13% in 2022, while the deepest fall reached 83.08% in 2022.
  • Over 3 years, Revenue stood at $23000.0 in 2021, then skyrocketed by 95.65% to $45000.0 in 2022, then soared by 100.0% to $90000.0 in 2025.
  • According to Business Quant data, Revenue over the past three periods came in at $90000.0, $45000.0, and $45000.0 for Q3 2025, Q3 2022, and Q2 2022 respectively.